## Highlights of This Issue 5915

### SPECIAL FEATURES

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5917</td>
<td>Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy</td>
<td>William E. Carson III</td>
</tr>
<tr>
<td>5920</td>
<td>Toward a Better Understanding of Race and Cancer</td>
<td>Otis W. Brawley</td>
</tr>
</tbody>
</table>

#### CCR Drug Updates

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5923</td>
<td>Pazopanib in Renal Cell Carcinoma</td>
<td>James E. Ward and Walter M. Stadler</td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5928</td>
<td>Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis</td>
<td>Xin Lu and Yibin Kang</td>
</tr>
<tr>
<td>5936</td>
<td>Targeting RET Receptor Tyrosine Kinase Activation in Cancer</td>
<td>John E. Phay and Manisha H. Shah</td>
</tr>
</tbody>
</table>

#### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5942</td>
<td>Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion</td>
<td>Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel</td>
</tr>
<tr>
<td>5956</td>
<td>Translating Clinical Trials into Meaningful Outcomes</td>
<td>Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf</td>
</tr>
<tr>
<td>5963</td>
<td>Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction?</td>
<td>Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch</td>
</tr>
<tr>
<td>5972</td>
<td>Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?</td>
<td>Tito Fojo and David R. Parkinson</td>
</tr>
</tbody>
</table>

#### CCR Focus

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5950</td>
<td>Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease</td>
<td>Susan E. Bates</td>
</tr>
<tr>
<td>5951</td>
<td>Value and Cancer Care: Toward an Equitable Future</td>
<td>Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock</td>
</tr>
</tbody>
</table>

---

The Journal of Clinical and Translational Research

December 15, 2010 • Volume 16 • Number 24

The Journal of Clinical and Translational Research iii www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on April 12, 2017. © 2010 American Association for Cancer Research.
**HUMAN CANCER BIOLOGY**

**6009**
IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer  
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

**CANCER THERAPY: PRECLINICAL**

**6019**
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model  
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann

**6029**
Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma  
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

**6040**
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations  

**IMAGING, DIAGNOSIS, PROGNOSIS**

**6083**
Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification  
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

**6093**
Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer  

**6100**
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study  

**CANCER THERAPY: CLINICAL**

**6122**
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma  
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

**6132**
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORA8-009 in Patients with Mesothelin-Expressing Cancers  
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

Letters to the Editor

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?
Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133⁺ glioblastoma stem-like cell line GBMJ1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.
Clinical Cancer Research

16 (24)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.